The potential of a drug to be endured. Also known as ‘Tolerability’. Source: EU Clinical Trials Register
A definition of the general outline of what the clinical trial will investigate. Source: EU Clinical Trials Register
Results that are measured at the end of a study, in addition to the main result (primary endpoint) to see if a given treatment worked. Secondary endpoints can explore other aspects of the treatment. Source: EU Clinical Trials Register
A description of the secondary objectives of the trial as defined by secondary end points. Source: EU Clinical Trials Register
A trial where the subjects (healthy volunteers or patients) included in the trial doesnt know which treatment they are given but the investigator does. Source: EU Clinical Trials Register
A trial is conducted in a single centre (clinical trial site) in the EU Country concerned by the application. Source: EU Clinical Trials Register
Means the use of autologous (emanating from the patient himself), allogeneic (coming from another human being) or xenogeneic (coming from animals) somatic living cells, the biological characteristics of which have been substantially altered as a result of their manipulation to …
Organisation or Pharmaceutical company providing monetary or material support for the conduct of the trial. Source: EU Clinical Trials Register
Formulation specifically developed for paediatric use. Source: EU Clinical Trials Register
Clinical trial includes subjects (healthy volunteers or patients), who are considered to be part of a population at risk. Source: EU Clinical Trials Register